The share of domestic diabetes drugs in the total sales volume for the first three quarters of 2025 was almost 60% in volume and 39.2% in value terms. This is reported by Rossiyskaya Gazeta with reference to the Ministry of Industry and Trade.
According to the State Register of Medicinal Products (GRLS), 590 drugs for diabetes treatment under 59 international nonproprietary names (INNs) are registered in Russia. Of these, 29 drugs by INN are produced in the country via a full production cycle starting with substance synthesis, while another 14 are localized at the finished dosage form stage.
The Ministry of Industry and Trade noted that over the past 5 years, modern drugs for treating type 2 diabetes have appeared on the Russian market. Primarily, these are generics of GLP-1 receptor agonists (liraglutide and semaglutide), as well as dual GIP and GLP-1 agonists (tirzepatide). These drugs effectively lower blood sugar levels and promote weight loss.
The emergence of new domestic anti-diabetic drugs with full production localization has increased treatment accessibility and led to price reductions, believes Natalya Malykh, Vice President for Business Development at Pharmasintez Group. According to Alexander Bykov, Director of Healthcare Economics at R-Pharm, all necessary diabetes drugs are now fully available on the Russian pharmaceutical market. Meanwhile, the company Alfarm estimates the volume of the Russian diabetes drug market, including insulins, at approximately 120 billion rubles.